Swiss stocks - Factors to watch on July 9 July 9 - Here are some of the main factors that may affect Swiss stocks on Tuesday: ROCHE ROG.S Genentech, a unit of Roche Group ROG.S, said on Monday it has re-launched its eye implant, Susvimo, in the United States, following the end of a voluntary recall, and the device will be available to patients in the coming weeks.

UPDATE 1-Roche launches recalled eye implant in US Adds background on implant in paragraphs 2 to 4 July 8 (Reuters) - Genentech, a unit of Roche Group ROG.S , said on Monday it has re-launched its eye implant, Susvimo, in the United States, following the end of a voluntary recall, and the device will be available to patients in the coming weeks. The implant was approved by the U.S.

Roche reintroduces recalled eye implant in US July 8 (Reuters) - Genentech, a unit of Roche Group ROG.S , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall. Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar

BRIEF-Roche To Reintroduce Susvimo In The US July 8 (Reuters) - ROCHE HOLDING AG ROG.S : ANNOUNCED REINTRODUCTION OF SUSVIMO® (RANIBIZUMAB INJECTION) 100 MG/ML FOR INTRAVITREAL USE VIA OCULAR IMPLANT FOR TREATMENT OF PEOPLE IN UNITED STATES FDA HAS APPROVED UPDATES TO SUSVIMO, WHICH WILL BE AVAILABLE TO US RETINA SPECIALISTS AND PATIENTS WITH NAMD

BRIEF-Genentech To Reintroduce Susvimo For People With Wet Age-Related Macular Degeneration (AMD) July 8 (Reuters) - GENENTECH- GENENTECH- CO TO REINTRODUCE SUSVIMO FOR PEOPLE WITH WET AGE-RELATED MACULAR DEGENERATION (AMD) GENENTECH- FDA HAS APPROVED UPDATES TO SUSVIMO, WHICH WILL BE AVAILABLE TO U.S. RETINA SPECIALISTS AND PATIENTS WITH WET AMD I

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo

UPDATE 2-European shares fall on French election uncertainty; log weekly gain For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 down 0.2%, eyes on French election UK midcaps close at one-month high Aixtron rallies on strong orders Updated at 1600 GMT By Shristi Achar A, Sruthi Shankar and Jesus Calero July 5 (Reuters) - European shares fell on Friday, weighed down by losses in banks and energy stocks as investors became more caut

BRIEF-Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs) July 5 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES GENENTECH’S VABYSMO PREFILLED SYRINGE (PFS) FOR THREE LEADING CAUSES OF VISION LOSS DESIGNED TO SIMPLIFY ADMINISTRATION, VABYSMO PFS PROVIDES RETINA SPECIALISTS A READY-TO-USE OPTIO VABYSMO PFS IS FIRST AND ONLY SYR

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq

UPDATE 2-Roche to halt trial in latest setback for lung cancer immunotherapy Rewrites throughout, adds shares in paragraph 4 By Rachel More and Ludwig Burger BERLIN, July 4 (Reuters) - Roche ROG.S will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co MRK.N , casting further doubt on the drug candidate pioneered by the Swiss company.

Roche to halt trial for lung cancer treatment after 'disappointing' results BERLIN, July 4 (Reuters) - Roche ROG.S intends to halt a trial for combined lung cancer treatment using a new immunotherapy called tiragolumab after results fell short of efficacy targets, the Swiss drugmaker said on Thursday. The trial, dubbed SKYSCRAPER-06, evaluates tiragolumab plus Roche's established drug Tecentriq and chemotherapy.

BRIEF-Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy July 4 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE PROVIDES UPDATE ON PHASE II/III SKYSCRAPER-06 STUDY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER SKYSCRAPER-06 EVALUATING TIRAGOLUMAB PLUS TECENTRIQ AND CHEMOTHERAPY DID NOT MEET PRIMARY ENDPOINTS OF PROGRESSION-FREE SUR

Swiss stocks - Factors to watch on July 4 ZURICH/GDANSK, July 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS AG UBSG.S U.S. bank State Street STT.N has won a mandate to act as custodian bank for a multibillion-dollar compensation fund of the Swiss federal government that was previously at UBS, authorities said on Wednesday.

UPDATE 1-Roche sues Stanford University, cancer-detection startup over trade secrets Updates July 2 story to add response from Foresight in paragraph 3 By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products.

Swiss stocks - Factors to watch on July 3 July 3 - Here are some of the main factors that may affect Swiss stocks on Wednesday: Roche ROG.S Roche has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products COMPANY STATEMENTS Dormakaba DOKA.S - says René Peter appointed CFO ad interim ANALYSTS' VIEWS VAT GROUP AG VACN.S - JEFFERIES RAIS

Roche sues Stanford University, cancer-detection startup over trade secrets By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products. Roche said in the complaint filed on Monday that Stanford University professors Maximilian Diehn and Ash Alizadeh, whose technology Roche acquired in 20

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri

Swiss stocks - Factors to watch on July 2 ZURICH/GDANSK, July 2 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: GIVAUDAN SA GIVN.S The company completed the acquisition of B.Kolormakeup & Skincare. LOGITECH INTERNATIONAL SA LOGN.S A chairperson informed the management board of the 2025 transition plan . PSP SWISS PROPERTY AG PSPN.S The company acquired a commercial property in Geneva for 58 million Swiss francs.

Financials lift Japanese shares on rate-hike speculation By Brigid Riley TOKYO, July 2 (Reuters) - Japan's Nikkei share average rose on Tuesday, buoyed by financial sector stocks climbing on speculation that the Bank of Japan (BOJ) might raise interest rates again in the near future amid a weakening yen. The Nikkei .N225 was up 0.38% at 39,780.58 by the midday break.